References: |
Product Reference:
?GSK-3-selective inhibitors derived from Tyrian purple indirubins: L. Meijer, et al.; Chem. Biol. 10, 1255 (2003)
?Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases: P. Polychronopoulos, et al.; J. Med. Chem. 47, 935 (2004)
?The GSK-3 inhibitor BIO promotes proliferation in mammalian cardiomyocytes: A.S. Tseng, et al.; Chem. Biol. 13, 957 (2006)
?7-Bromoindirubin-3'-oxime induces caspase-independent cell death: J. Ribas, et al.; Oncogene 25, 6304 (2006)
?Inverse in silico screening for identification of kinase inhibitor targets: S. Zahler, et al.; Chem. Biol. 14, 1207 (2007)
?An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted indirubins: V. Myrianthopoulos, et al.; J. Med. Chem. 50, 4027 (2007)
?Indirubin derivatives inhibit malignant lymphoid cell proliferation: A. Chebel, et al.; Leuk. Lymphoma 50, 2049 (2009)
?6-Bromoindirubin-3'-Oxime Inhibits JAK/STAT3 Signaling and Induces Apoptosis of Human Melanoma Cells: L. Liu, et al.; Cancer Res. 71, 3972 (2011)
? |